CClinicalTrials.gg
CompletedNCT03811626Updated Jan 24, 2019

Efficacy of Multidimensional Management of Mild Traumatic Brain Injury

An interventional study of cognitive-behavioral rehabilitation in Mild Traumatic Brain Injury, sponsored by Institut de Recherche sur la Moelle épinière et l'Encéphale. Completed at 6 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-24.

Sponsored by Institut de Recherche sur la Moelle épinière et l'Encéphale · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 6 years 9 months after the study started (first participant enrolled Apr 2012, registered Jan 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Unfavorable outcomes (UO) are seen in 15 to 20% of patients with mild traumatic brain injury (mTBI). Early identification of patients at risk for UO is crucial for suitable management to be initiated, increasing their chances for a return to a normal life. The investigators previously developed a diagnostic tool enabling early identification (8 to 21 days after the injury) of patients likely to develop UO. In the present study, the investigators examined the value and beneficial effects of early multidimensional management (MM) on prognosis. The investigators used a diagnostic tool to classify 221 mTBI patients as UO (97) or FO (favorable outcome) (124). Patients whose initial risk factors point to UO are at risk of developing post-concussion syndrome (PCS). UO patients were randomized into 2 groups: a group that underwent MM (cognitive-behavioral rehabilitation) (34) and a group with no specific management (46). At 6 months, these 2 groups were compared and the impact of MM on outcome was assessed. Among patients initially classified as FO (101), 95% had FO at 6 months and only 5 had PCS as defined by DSM-IV classification. Of the UO patients who received MM, 94% had no PCS 6 months after injury, whereas 52% of the UO patients who did not receive MM had persistent PCS. The effect of MM on the recovery of patients at 6 months, once adjusted for the main confounding factors, was statistically significant (p\<0.001). These results show that the initiation of MM after early identification of at-risk mTBI patients can considerably improves their prognosis.

02

Conditions studied

  • Mild Traumatic Brain Injury

Keywords

  • Mild TBI
  • quality of life
  • coping strategies
  • symptoms
  • neuropsychological tests
  • pain
  • memory reactive
  • Cognitive dimension
03

In context

Brain Injuries

2,113 studies on the registry are indexed under Brain Injuries; 385 are open to participants now.

This study's enrollment of 221 is above the median of 48 across 1,331 interventional studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

Institut de Recherche sur la Moelle épinière et l'Encéphale is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged 18 to 65 who have suffered mTBI, have health care coverage, who understand French, who can be followed for 6 months, and who are able to understand, reply, and cooperate.

Exclusion criteria

Exclusion Criteria:

  • Patient intubated and/or ventilated and/or sedated upon arrival at hospital
  • Patient with injury to the medulla and with neurological signs or multiple injuries (at least 1 of which is life-threatening)
  • Brain injury incurred during a suicide attempt
  • Patient presenting psychiatric or psychological disorders that are debilitating and/or interfere with follow-up and/or evaluation
  • Psychoactive treatment ongoing at the time of injury
  • History of hospitalization in specialized a psychiatric setting and/or sick leave for psychological reasons
  • Patient with a neurological disorder
  • Patient with substance dependence
  • Subject under guardianship or wardship
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    Intervention

    Patient who underwent cognitive-behavioral rehabilitation

    Procedure: cognitive-behavioral rehabilitation

  • No intervention
    Comparator

    Patient with no specific management

Interventions

  • Procedurecognitive-behavioral rehabilitation

    Combination of clinical examination and neuropsychological and psychological tests

06

What researchers measure

Primary outcomes

  1. Change in quality of life

    Change in quality of life assessed by QOLIBRI (Quality of Life after Brain Injury) Scale - QOLIBRI scale assess health-related quality of life (HRQoL) of individuals after traumatic brain injury. QOLIBRI is a comprehensive questionnaire with 37 items covering six dimensions of HRQoL after TBI. The QOLIBRI scores are reported on a 0-100 scale , where 0=worst possible quality of life and 100=best possible quality of life.

    Time frame: Baseline, 6 months -

07

Study locations

6 sites
  • Chu Bicetre
    Le Kremlin-Bicêtre, France
  • Chu Montpellier
    Montpellier, France
  • Chu Bichat/Beaujon
    Paris, France
  • CHU St ANTOINE
    Paris, France
  • Chu Tenon
    Paris, France
  • Chu Rouen
    Rouen, France
08

References and documents

Publications

  • Caplain S, Chenuc G, Blancho S, Marque S, Aghakhani N. Efficacy of Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury for Preventing Post-concussional Syndrome in Individuals With High Risk of Poor Prognosis: A Randomized Clinical Trial. Front Neurol. 2019 Sep 4;10:929. doi: 10.3389/fneur.2019.00929. eCollection 2019. PubMed 31551902 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03811626
Lead sponsor
Institut de Recherche sur la Moelle épinière et l'Encéphale
Responsible party
Sponsor
First posted
Jan 22, 2019
Start date
Apr 1, 2012
Primary completion
Jun 30, 2013
Completion
Jun 30, 2013
Last update
Jan 24, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion